Charles River Posts Loss In Q2; Increases 2026 Guidance For Revenue, Non-GAAP EPS

rttnews.com · 2026-08-05

Charles River Laboratories International (CRL) reported a second quarter net loss attributable to common shareholders of $1.48 million compared to net income of $52.

TickrTrends take: Charles River Laboratories reported a loss in the second quarter while simultaneously raising its full-year 2026 guidance for both revenue and non-GAAP earnings per share. This combination of near-term losses alongside increased forward guidance suggests management confidence in future profitability, though TickrTrends currently assesses the stock as overvalued within the Healthcare sector. Investors focused on valuation should monitor whether the company can translate its optimistic 2026 outlook into actual earnings growth that would justify the current stock price.

Read the full story at rttnews.com →